StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

Earnings

CRISPR Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$12.67M
+1325.1% on a year earlier
EPS, Q3 FY2026
-$1.15
-$1.17 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of CRISPR Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 2, 2026after the close$12.67M+1325.1%-$1.15Release
Q2 FY2026ended Jun 30, 2026Aug 3, 2026after the close$10.18M+1041.4%-$0.94Release
Q1 FY2026ended Mar 31, 2026May 4, 2026after the close$1.46M+68.6%-$1.28Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026after the close$864.00K–-$1.37Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025before the open$889.00K+47.7%-$1.17Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025after the close$892.00K+72.5%-$2.40Release
Q1 FY2025ended Mar 31, 2025May 6, 2025after the close$865.00K+71.6%-$1.58Release
Q4 FY2024ended Dec 31, 2024Feb 11, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024before the open$602.00K–-$1.01Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024after the close$517.00K-99.3%-$1.49Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close$504.00K-99.5%-$1.43Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

CRISPR Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When CRISPR Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases CRISPR Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. News
  5. News
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?